Levetiracetam Solution
Product Images NDC 0472-0235

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 0472-0235). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Actavis Pharma, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Total Daily (Image 1)

A mathematical formula is shown for calculating total daily dose in mL/day based on daily dose in mg/kg/day, patient weight in kg, and solution strength of 100 mg/mL. The formula demonstrates dose calculation for Levetiracetam oral solution.*

FDA Label Image

Levetiracetam-figure-5 (Image 10)

A bar graph comparing the percentage of patients responding to Placebo versus Levetiracetam treatment. The y-axis shows the percentage of patients, with Placebo at 45.2% and Levetiracetam at 72.2%. Patient sample sizes are indicated as 84 for Placebo and 79 for Levetiracetam.*

FDA Label Image

Image (Image 11)

Label for Levetiracetam Oral Solution, USP 100 mg/mL by Actavis Pharma, Inc. The label shows dosage strength 100 mg/mL, provides storage instructions at 25°C (77°F), and advises dispensing in a light-resistant container with a child-resistant closure. The package contains one pint (473 mL) and includes barcodes and lot/expiration coding area. It is marked Rx only.*

FDA Label Image

0.85 Image (Image 2)

A text panel showing a formula to calculate creatinine clearance (CLcr), involving age, weight, serum creatinine, and a factor for female patients. This is unrelated to the Levetiracetam oral solution product itself.*

FDA Label Image

1.73 Image (Image 3)

The image shows a formula calculation related to clearance (Clcr) normalized for body surface area (BSA). It presents the formula for Clcr in mL/min/1.73 m² as Clcr in mL/min divided by subject BSA in m², then multiplied by 1.73.*

FDA Label Image

0ccff95d-figure-04 (Image 4)

Chemical structure of levetiracetam, showing its molecular arrangement including the pyrrolidone ring, the ethyl group, and amide functional groups, as represented in the image.*

FDA Label Image

Figure1leve (Image 5)

A bar chart depicting the percentage of patients across three groups: Placebo (7.4%), Levetiracetam 1000 mg/day (37.1%), and Levetiracetam 3000 mg/day (39.6%). The y-axis represents the percentage of patients, and the x-axis lists treatment groups. Asterisks indicate statistical significance for the Levetiracetam groups.*

FDA Label Image

Figure2leve (Image 6)

A bar chart showing percentages of patients by treatment type: Placebo (6.3%), Levetiracetam 1000 mg/day (20.8%), and Levetiracetam 2000 mg/day (35.2%). Each bar is labeled with the number of patients in each group (Placebo N=111, Levetiracetam 1000 mg/day N=106, Levetiracetam 2000 mg/day N=105) and includes markers indicating statistical significance.*

FDA Label Image

Figure3leve (Image 7)

A bar chart comparing the percentage of patients for placebo and Levetiracetam treatment groups. The x-axis shows Placebo (N=104) and Levetiracetam 3000 mg/day (N=180). The y-axis is labeled as % of Patients, ranging from 0% to 45%. The placebo group bar reaches 14.4%, and the Levetiracetam group bar reaches 39.4%, marked with an asterisk above it.*

FDA Label Image

Figure 4 (Image 8)

A bar graph comparing the percentage of patients showing a certain response between a placebo group (19.6%, N=97) and a levetiracetam group (44.6%, N=101). The y-axis represents the percentage of patients, ranging from 0% to 45%, with a marked asterisk on the levetiracetam bar.*

FDA Label Image

Fig5 (Image 9)

A bar graph comparing the percentage of patients between two groups: Placebo and Levetiracetam. The vertical axis shows the percent of patients, with bars displaying 19.6% for Placebo (N=51) and 43.1% for Levetiracetam (N=58). An asterisk marks the Levetiracetam bar.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.